IP Library Granted Patent US 11,191,910
Granted Patent B2
US 11,191,910 · App. 16/695,147 · Granted Dec 7, 2021

Medical unit dose container

Inventors: John D. Hoekman (Seattle, WA); Alan Brunelle (Woodinville, WA); Craig Kohring (Seattle, WA); Christopher Fuller (Seattle, WA)
Assignee: Impel Neuropharma, Inc.
A61M15/0028A61M11/006A61M11/02A61M15/0001A61M15/003A61M15/004A61M15/009A61M15/0033A61M15/0035A61M15/0036A61M15/0086A61M15/08A61M2207/00A61M2210/0618
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,191,910
App. No.
16/695,147
Granted
Dec 7, 2021
Kind
B2
Abstract

A unit dose container for the containment of an intranasal formulation for use with the POD device.

Claims (34)

1. A device for delivering a compound to an olfactory region of a nasal cavity comprising:

a canister configured to contain a propellant,

a tip configured to removably couple to a housing body of the device, the tip comprising:

a container cavity configured to receive a unit dose container, the unit dose container configured to contain the compound,

a diffuser configured to be in communication with the canister such that propellant exiting the canister travels through the diffuser, and

a nozzle in communication with the container cavity; and

a puncture member that is configured to, upon coupling the tip to the housing body, puncture an end of the unit dose container such that following contact with the diffuser, the diffused propellant contacts the compound contained in the unit dose container,

wherein the device is capable of delivering the compound to the olfactory region of the nasal cavity.

2. The device of claim 1 , further comprising an additional puncture member, wherein the additional puncture member is configured to puncture a second end of the unit dose container.

3. The device of claim 1 , wherein the puncture member has an angle of puncture between 15 degrees and 90 degrees, inclusive.

4. The device of claim 1 , wherein the puncture member further comprises a side orifice.

5. The device of claim 1 , wherein the compound is an intranasal formulation.

6. The device of claim 1 , wherein the end of the unit dose container further includes a rubber stopper or a foil seal or combinations thereof.

7. The device of claim 1 , wherein the end of the unit dose container includes a puncture area.

8. The device of claim 7 , wherein the puncture area is a dimple.

9. The device of claim 1 , wherein the puncture member is composed of metal or a polymer or combinations thereof.

10. The device of claim 1 , further comprising a connection channel having a first end and a second end, where the first end is coupled to the canister and the second end is coupled to the diffuser, wherein a diameter of the diffuser across an opening of the container cavity is greater than a diameter of the connection channel.

11. The device of claim 1 , wherein the puncture member comprises a rear puncture member positioned on the housing body, the device further comprising a front puncture member positioned on the tip, wherein each puncture member is configured to puncture a respective end of the unit dose container.

12. The device of claim 1 , wherein the puncture member comprises a hollow channel for delivery of the propellant into the unit dose container.

13. The device of claim 1 , wherein the puncture member is composed of a porous material for delivery of the propellant into the unit dose container.

14. The device of claim 1 , wherein the tip is configured to translate relative to the housing body.

15. The device of claim 1 wherein the tip and the housing body each have respective threaded interfaces that are configured to mate.

16. A device for delivering a compound to an olfactory region of a nasal cavity comprising:

a canister configured to contain a propellant,

a tip configured to removably couple to a housing body of the device, the tip comprising:

a container cavity configured to receive a unit dose container, the unit dose container configured to contain the compound,

a diffuser configured to be in communication with the canister such that propellant exiting the canister travels through the diffuser, and

a nozzle in communication with the container cavity; and

a puncture member that is configured to upon coupling the tip to the housing body, puncture an end of the unit dose container,

wherein the device is capable of delivering the compound to the olfactory region of the nasal cavity.

17. The device of claim 16 , wherein the puncture member is porous such that, upon actuation, propellant exiting the canister comes into contact with the puncture member.

18. The device of claim 16 , wherein the puncture member is a rear puncture member configured to puncture a proximal end of the unit dose container, the device further comprising a front puncture member positioned on the tip and configured to puncture a distal end of the unit dose container.

19. The device of claim 16 , further comprising one or more ribs along the length of the unit dose container.

20. The device of claim 16 , wherein an end of the unit dose container includes a puncture area.

Assignments (11)
SECURITY INTEREST Recorded Jun 5, 2025
From: WOODWARD SPECIALTY LLC
To: ALTER DOMUS (US) LLC
Reel/Frame 071324/0602 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2024
From: JN BIDCO LLC
To: WOODWARD SPECIALTY LLC
Reel/Frame 067062/0344 →
SECURITY INTEREST Recorded Mar 20, 2024
From: JN BIDCO LLC
To: ALTER DOMUS (US) LLC, AS COLLATERAL AGENT
Reel/Frame 066837/0144 →
RELEASE OF SECURITY INTEREST Recorded Feb 28, 2024
From: OAKTREE FUND ADMINISTRATION, LLC
To: IMPEL PHARMACEUTICALS, INC.
Reel/Frame 066699/0566 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2024
From: IMPEL PHARMACEUTICALS INC.
To: JN BIDCO LLC
Reel/Frame 066601/0479 →
CORRECTIVE ASSIGNMENT TO CORRECT THE REMOVAL OF APPLICATION NUMBERS 12866448 AND APLICATION NUMBER 14292481 PREVIOUSLY RECORDED AT REEL: 059790 FRAME: 0722. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded May 4, 2022
From: IMPEL NEUROPHARMA, INC.
To: IMPEL PHARMACEUTICALS INC.
Reel/Frame 059855/0252 →
CHANGE OF NAME Recorded Apr 25, 2022
From: IMPEL NEUROPHARMA, INC.
To: IMPEL PHARMACEUTICALS INC.
Reel/Frame 059790/0722 →
SECURITY INTEREST Recorded Mar 17, 2022
From: IMPEL NEUROPHARMA, INC.
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 059300/0390 →
RELEASE OF SECURITY INTEREST Recorded Jul 6, 2021
From: AVENUE VENTURE OPPORTUNITIES FUND, L.P.
To: IMPEL NEUROPHARMA, INC.
Reel/Frame 056758/0495 →
SECURITY INTEREST Recorded Nov 5, 2020
From: IMPEL NEUROPHARMA, INC.
To: AVENUE VENTURE OPPORTUNITIES FUND, L.P.
Reel/Frame 054287/0473 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 26, 2019
From: HOEKMAN, JOHN D.; FULLER, CHRISTOPHER; KOHRING, CRAIG; BRUNELLE, ALAN
To: IMPEL NEUROPHARMA, INC.
Reel/Frame 051563/0112 →
Continuity (3)
Continuation 14787455
Provisional Application 61816799 · Apr 28, 2013
Related Publication 20200101243A1 · Apr 2, 2020
Cited By (4)
US 1,116,097 US 12,336,959 US 12,544,511 US 12,673,161